Sai Life Sciences has a growing pipeline. Can earnings catch up?
Sai Life Sciences experienced strong revenue growth in FY26, with profits more than doubling. Its market capitalisation is around Rs 33,650 crore, with a trailing P/E of over 90x, indicating an unusual investment setup. The company operates as a Contract Research, Development and Manufacturing Organisation (CRDMO), providing services from discovery to commercial production.
Sai's growth is driven by high-quality customers, increasing wallet share, strong discovery growth, and a growing late-stage pipeline. The company's unique value lies in its ability to participate in the drug development process from early stages, which could lead to significant earnings if its pipeline converts into successful products.
Written by urgent.news from The Indian Express's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
